<DOC>
	<DOCNO>NCT00924807</DOCNO>
	<brief_summary>The purpose study evaluate safety new drug- sorafenib , administer time standard treatment , include hormonal therapy external beam radiotherapy .</brief_summary>
	<brief_title>Safety Study Sorafenib With Androgen Deprivation Radiotherapy Treat Prostate Cancer</brief_title>
	<detailed_description>Leuprolide acetate ( luteinizing hormone release hormone ( LHRH ) agonist ) Bicalutamide ( anti-androgen ) hormonal agent commonly use reduce testosterone blood level prostate cancer treatment . Intensity modulate external beam radiotherapy standard treatment localized prostate cancer . Previous study show combine hormonal therapy radiation effective radiation alone . Unfortunately , significant percentage ( 50-75 % ) patient still relapse . Sorafenib reduce growth cancer cell proven effective treatment solid tumor include kidney liver cancer . This drug approve FDA treatment kidney liver cancer . The study investigator believe add sorafenib standard treatment , comprise hormonal therapy radiation , might effective standard hormonal therapy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Patients must histologically confirm intermediate high risk prostate adenocarcinoma . Intermediate risk disease comprise T2b/c tumor , Gleason 7 histology , PSA 1020 . High risk tumor comprise T34 , Gleason 8 high histology , PSA great 20 . Age &gt; 18 year . Life expectancy great 5 year . Patients must normal organ marrow function . No pelvic lymph node metastasis base pelvic CT scan MRI . No bone metastasis . A whole body bone scan require rule metastatic disease . Any previous , radiotherapy , chemotherapy , 4 week androgen deprivation hormonal therapy treatment prostate adenocarcinoma . Patients may receive investigational agent . History allergic reaction attribute compound similar chemical biologic composition sorafenib agent use study . Known human immunodeficiency virus ( HIV ) infection chronic Hepatitis B C. Patients receive anticoagulation treatment agent warfarin heparin allow participate .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Combined Androgen Blockade</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Sorafenib</keyword>
</DOC>